FDA GMP Initiative Shifts Warning Letter Review Back To Centers
This article was originally published in The Tan Sheet
Executive Summary
The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of FDA's initiative to create a risk-based approach to pharmaceutical manufacturing
You may also be interested in...
Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei
Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei
Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei